In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Fortress Biotech (FBIO), with a price target of $11. The company’s shares opened today at $2.15.
Pantginis commented:
“Valuation and risks to price target achievement. We reiterate our Buy rating and $11 price target. Our valuation is based on our clinical net present value (NPV) model, which derives value from across Fortress’ subsidiaries. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.”
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -19.3% and a 27.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Dova Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Fortress Biotech with a $11 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.54 and a one-year low of $0.49. Currently, Fortress Biotech has an average volume of 629.1K.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fortress Biotech, Inc. engages in the development and commercialization of novel pharmaceutical and biotechnology products. It operates through the following segments: Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development, and National. The National segment consists of National Holdings Corporation, an independent brokerage company.
